The role of lipids and uremic toxins in cardiovascular disease in CKD.
Lipid abnormalities and uremic toxins are features of chronic kidney disease (CKD) and may influence cardiovascular outcomes in CKD patients. Recent data suggest that uremic toxins may modulate lipoprotein levels and composition (e.g., oxidation or carbamylation) and enhance the cardiovascular toxicity of lipoproteins in CKD patients.
Division of Nephrology, Ambroise Paré Hospital, Paris Ile de France Ouest University (UVSQ), 09 Avenue Charles de Gaulle, Boulogne Billancourt, 92100, Paris, France, ziad.massy@apr.aphp.fr.
Ziad A
ZA
Massy
D002318:Cardiovascular Diseases / Q000209:etiology*; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology*; D008074:Lipoproteins / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000503:physiopathology*; D014118:Toxins, Biological / Q000502:physiology*; D014511:Uremia / Q000503:physiopathology*
D008074:Lipoproteins; D014118:Toxins, Biological; C026865:uremia middle molecule toxins